Beta Bionics (BBNX) leads innovation in the diabetes treatment market with its groundbreaking iLet Bionic Pancreas technology ...

Underwriters have a 30-day option to buy an additional 1.8 million shares. Beta Bionics also agreed to sell 1 million shares ...

Beta Bionics announced today that it went public after pricing a significantly upsized initial public offering (IPO).

The so-called 'hybrid closed-loop' system comprises a blood glucose sensor, the MiniMed 670G insulin pump and an infusion ... Beta Bionics' iLet has shown promise in clinical trials so far.

Insulin overdose symptoms can include confusion, fatigue, irritability, shaking, and other signs of low blood sugar (hypoglycemia). Insulin dosing is a multistep process that often requires careful ...

The commercialized Beta Bionics device, named iLet, received FDA clearance in 2023 for patients age 6 and older. Unlike traditional insulin pumps that require users to keep track of their ...

After hours: February 3 at 4:06:48 PM EST ...

Oil company Natural Resources and medical-device maker Beta Bionics shrug off a down market to gain in their trading debuts.

Beta Bionics makes the iLet Bionic Pancreas pump, which the Irvine ... device to use "adaptive closed-loop algorithms" to adjust insulin doses. The company added 2 million shares to the IPO ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...